METTL3 and nonpapillary renal cell carcinoma: Dysregulation of METTL3 has emerged as a hallmark of ccRCC, where it drives oncogenesis through methyltransferase-dependent RNA modification (e.g., enhancing pro-tumorigenic mRNA translation) and methyltransferase-independent signaling (e.g., activating PI3K/AKT pathways) (Mao et al., 2022; Luo et al., 2020; Dou et al., 2023; Schöller et al., 2018; Zeng et al., 2024).